These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28030784)

  • 1. Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.
    Jochems A; Schouwenburg MG; Leeneman B; Franken MG; van den Eertwegh AJ; Haanen JB; Gelderblom H; Uyl-de Groot CA; Aarts MJ; van den Berkmortel FW; Blokx WA; Cardous-Ubbink MC; Groenewegen G; de Groot JW; Hospers GA; Kapiteijn E; Koornstra RH; Kruit WH; Louwman MW; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; Wouters MW; van der Hoeven JJ
    Eur J Cancer; 2017 Feb; 72():156-165. PubMed ID: 28030784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry].
    van Zeijl MCT; van den Eertwegh AJM; Wouters MWJM; Jochems A; Schouwenburg MG; Haanen JBAG; Aarts MJ; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn E; Koornstra RH; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven KJM
    Ned Tijdschr Geneeskd; 2018 Jun; 162():. PubMed ID: 30040270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.
    Jochems A; Leeneman B; Franken MG; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; Groenewegen G; de Groot JWB; Haanen JBAG; Hospers GAP; Kapiteijn E; Koornstra RH; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; Uyl-de Groot CA; van der Hoeven KJM
    Anticancer Drugs; 2018 Jul; 29(6):572-578. PubMed ID: 29659371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upcoming strategies for the treatment of metastatic melanoma.
    Spagnolo F; Queirolo P
    Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.
    Menzies AM; Long GV
    Eur J Cancer; 2013 Oct; 49(15):3229-41. PubMed ID: 23870385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.
    Franken MG; Leeneman B; Jochems A; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; de Groot JWB; van der Hoeven KJM; Hospers GAP; Kapiteijn E; Koornstra R; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; van Zeijl M; Haanen JBAG; Uyl-de Groot CA
    Anticancer Drugs; 2018 Jul; 29(6):579-588. PubMed ID: 29634490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
    Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C
    Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
    Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
    Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
    Di Giacomo AM; Ascierto PA; Pilla L; Santinami M; Ferrucci PF; Giannarelli D; Marasco A; Rivoltini L; Simeone E; Nicoletti SV; Fonsatti E; Annesi D; Queirolo P; Testori A; Ridolfi R; Parmiani G; Maio M
    Lancet Oncol; 2012 Sep; 13(9):879-86. PubMed ID: 22894884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant treatment for melanoma in clinical practice - Trial versus reality.
    de Meza MM; Ismail RK; Rauwerdink D; van Not OJ; van Breeschoten J; Blokx WAM; de Boer A; van Dartel M; Hilarius DL; Ellebaek E; Bonenkamp HJ; Blank CU; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; Boers-Sonderen MJ; de Groot JWB; Haanen JB; Hospers GAP; Kapiteijn EW; Piersma D; van Rijn RS; van der Veldt AAM; Vreugdenhil A; Westgeest HM; van den Eertwegh AJM; Suijkerbuijk KPM; Wouters MWJM
    Eur J Cancer; 2021 Nov; 158():234-245. PubMed ID: 34600790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
    Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
    JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New drugs in melanoma: it's a whole new world.
    Eggermont AM; Robert C
    Eur J Cancer; 2011 Sep; 47(14):2150-7. PubMed ID: 21802280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
    Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
    Ascierto PA; Simeone E; Sileni VC; Del Vecchio M; Marchetti P; Cappellini GC; Ridolfi R; de Rosa F; Cognetti F; Ferraresi V; Testori A; Queirolo P; Bernengo MG; Guida M; Galli L; Mandalà M; Cimminiello C; Rinaldi G; Carnevale-Schianca F; Maio M
    Cancer Invest; 2014 May; 32(4):144-9. PubMed ID: 24484235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
    Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
    Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry.
    van Zeijl MCT; de Wreede LC; van den Eertwegh AJM; Wouters MWJM; Jochems A; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven JJM; Haanen JBAG
    Eur J Cancer; 2021 Feb; 144():242-251. PubMed ID: 33373869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Melanoma].
    Uhara H
    Gan To Kagaku Ryoho; 2016 Apr; 43(4):404-7. PubMed ID: 27220785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.